An interesting question that arises from this ruling is whether Cipla can export to a country which has issued a compulsory license under the Doha Declaration?
Another issue on which the Division Bench has ruled is that only Cipla may manufacture a generic version of Tarceva and that no other generic manufacturer may use the judgment of the single judge as a precedent to enter the fray. This really doesn’t make sense since other generic manufacturers are free to follow Cipla’s strategy – that is manufacture the drug and wait to be sued by Roche. To the best of my knowledge there is nothing to stop other generics from not doing so.
The matter is posted for its next hearing on 12th of May.